ArticleParasites & vectors2025
Oral administration of recombinant Bacillus subtilis spores induces protective immunity against Echinococcus granulosus infection in dogs.
Article in Parasites & vectors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEchinococcus granulosus sensu lato, a cestode that inhabits the small intestines of canids, causes cystic echinococcosis (CE), a globally distributed zoonosis, through its larval stage. Vaccination is a cost-effective strategy to control E. granulosus infection in dogs. However, although dogs are the definitive hosts and main sources of CE transmission, no effective oral vaccines are currently available for them.
methodsThree E. granulosus proteins, enolase (EgENO), severin (EgSev), and cyclophilin (EgCyc), were selected as novel oral vaccine candidates. These proteins were fused to the CotB spore-coat protein and expressed on the surface of Bacillus subtilis spores. A cocktail vaccine comprising the three recombinant spores was orally administered to beagles. Two weeks after the booster immunization, each dog was challenged with 70,000 protoscoleces. At 21 days post-infection, necropsies were performed to assess the intestinal parasite burden and calculate the worm reduction rates. Fecal and serum samples were collected weekly to measure secretory IgA, IgG, and cytokine responses. Histopathological analysis of intestinal tissues was also performed.
resultsThe cocktail vaccine reduced intestinal E. granulosus colonization by 62.26% (P < 0.05) compared with B. subtilis 168 spore-only controls. Vaccinated dogs developed both mucosal and humoral immune responses against E. granulosus antigens. By day 14 post-boost immunization, serum cytokine profiling revealed that levels of IFN-γ, IL-4, and IL-10 in the vaccinated group were significantly higher than those in the control group (P < 0.05). Histopathological analysis confirmed that the vaccine caused no adverse effects and alleviated the intestinal damage induced by the parasite.
conclusionsThis study demonstrates that B. subtilis spores serve as a safe and effective bacterial carrier to deliver E. granulosus antigens, supporting their potential in protecting dogs against E. granulosus infection. The heterogeneity in immune responses among vaccinated dogs should be addressed in future studies to secure consistent herd-level protection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.